Personalized, whole tumor-derived immunotherapies
Harnessing decades of research and multiple validated technologies, Imvax’s unique platform captures a tumor’s full antigen signature – and weaponizes it.
From clinical developments to novel research and our engagement with local communities — keep up with everything Imvax here.
Our team has a passion for patient care, a focus on innovation, and a commitment to working with integrity as part of our deeply collaborative environment. Sound like a fit for you?
Imvax is leveraging its unique immunotherapy platform to develop a pipeline of personalized, whole tumor-derived treatments targeting intractable solid tumors, which represent a majority of adult cancers.
Glioblastoma multiforme (glioblastoma, or GBM) is a brain cancer that is nearly always fatal. It is the most common malignant tumor that affects the central nervous system (CNS) and overall the third most common tumor of the brain and CNS.
A person newly diagnosed with GBM has a median overall survival (OS) or life expectancy of 12 to 15 months, and less than 6% of GBM patients survive to five years after diagnosis. The current standard of care treatment is based on surgery to remove as much of the tumor as possible. Surgery is typically followed by radiotherapy and chemotherapy.
IGV-001 is Imvax’s most advanced product candidate, in development to treat GBM. It has completed a Phase 1a in recurrent glioblastoma and a Phase 1b in newly diagnosed glioblastoma which in total dosed 46 patients. In the Phase 1b study, IGV-001 was well tolerated and multiple efficacy signals were observed. These included significant improvements in progression-free survival, radiographic evidence of tumor response, and multiple biomarkers changes that supported the presence of an immune response.
A randomized, placebo-controlled Phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma will be initiated in the fourth quarter of 2021. With positive data, Imvax plans to initiate a Phase 3 trial in the first quarter of 2023.
Glioblastoma multiforme (glioblastoma, or GBM) is a brain cancer that is nearly always fatal. It is the most common malignant tumor that affects the central nervous system (CNS) and overall the third most common tumor of the brain and CNS.
A person newly diagnosed with GBM has a median overall survival (OS) or life expectancy of 12 to 15 months, and less than 6% of GBM patients survive to five years after diagnosis. The current standard of care treatment is based on surgery to remove as much of the tumor as possible. Surgery is typically followed by radiotherapy and chemotherapy.
IGV-001 is Imvax’s most advanced product candidate, in development to treat GBM. It has completed a Phase 1a study in recurrent glioblastoma and a Phase 1b study in newly diagnosed glioblastoma which in total dosed 46 patients. In the Phase 1b study, IGV-001 was well tolerated and multiple efficacy signals were observed. These included significant improvements in progression-free survival , radiographic evidence of tumor response, and multiple biomarkers changes that supported the presence of an immune response.
A randomized, placebo-controlled Phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma will be initiated in the fourth quarter of 2021. With positive data, Imvax plans to initiate a Phase 3 trial in the first quarter of 2023.
Glioblastoma multiforme (glioblastoma, or GBM) is a brain cancer that is nearly always fatal. It is the most common malignant tumor that affects the central nervous system (CNS) and overall the third most common tumor of the brain and CNS.
A person newly diagnosed with GBM has a median overall survival (OS) or life expectancy of 12 to 15 months, and less than 6% of GBM patients survive to five years after diagnosis. The current standard of care treatment is based on surgery to remove as much of the tumor as possible. Surgery is typically followed by radiotherapy and chemotherapy.
IGV-001 is Imvax’s most advanced product candidate, in development to treat GBM. It has completed a Phase 1a study in recurrent glioblastoma and a Phase 1b study in newly diagnosed glioblastoma which in total dosed 46 patients. In the Phase 1b study, IGV-001 was well tolerated and multiple efficacy signals were observed. These included significant improvements in progression-free survival , radiographic evidence of tumor response, and multiple biomarkers changes that supported the presence of an immune response.
A randomized, placebo-controlled Phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma will be initiated in the fourth quarter of 2021. With positive data, Imvax plans to initiate a Phase 3 trial in the first quarter of 2023.
Imvax’s story began with a physician’s dedicated pursuit of new hope for patients with a deadly cancer. Today, our team is driven by that same mission to deliver transformational outcomes for people living with cancer through a new approach to personalized immunotherapy.
Patients’ care has always been at the center of our work. We are committed to the highest standards of professional excellence as we strive to rapidly advance a portfolio of investigational therapies, in collaboration with our network of clinical professionals.
As a company, we are obligated to ensure the safe and proper use of our investigational therapies and to provide access at the appropriate time, in the right manner and under the guidance of regulatory authorities, specifically the U.S. Food and Drug Administration (FDA).
If you or your physician have general questions regarding Imvax or our clinical work, or would like to connect with one of our patient advocates, please contact us at contact@imvax.com.
Imvax’s clinical studies can always be viewed at the database provided by clinicaltrials.gov.
Informed by decades of research, Imvax’s platform elegantly turns the complexity of a solid tumor against itself by capturing its complete antigenic signature and converting it into a highly immunostimulatory ‘training program’. This is designed to deliver both innate and adaptive immune stimulation to overcome the challenges of solid tumors’ variability and ability to suppress the immune system.
Imvax’s platform is a multi-step process designed to deliver personalized, whole tumor-derived immunotherapies. It relies on multiple validated technologies and can be incorporated into the standard of care for cancer. Click into the major two steps unique to Imvax’s platform to find out more.
After surgical removal, patient tumor samples undergo overnight tissue processing including radiation and treatment with an antisense therapy that stresses the cells toward an immunogenic cell death. This process promotes the release of the tumor’s entire antigenic signature along with immunostimulatory factors.
The tumor’s antigenic components and the antisense therapy (IMV-001) are then temporarily implanted in the patient within small proprietary chambers. These provide a controlled interface with the immune system via micropores.
The intended result of implanting the chamber is that the immune system absorb the tumor’s full antigenic signature, triggering innate immunity and the induction of a long-term adaptive immune response against remaining tumor tissue in the body.
This immune stimulation is augmented by the antisense therapy, IMV-001. This single-stranded nucleic acid is designed to act in multiple ways to enhance sensitization of the immune system to a tumor’s full, unique antigen signature.
Firstly, IMV-001 targets the IGF1R receptor, a cell growth controller common in tumors, but not most healthy cells.
IMV-001 binds to IGF1R in tumor cells to promote a specific kind of immunogenic tumor cell death which releases the tumor’s entire antigenic signature along with immunostimulatory factors.
Finally, IMV-001’s sequence includes a short element called a CpG motif. As IMV-001 diffuses out of the chamber, this motif activates nearby antigen-presenting cells, now laden with tumor antigens. These cells consequently traffic to local lymph nodes to activate the adaptive immune system.
Imvax’s platform bypasses the defenses of solid tumors and fully exposes their antigenic signature to an enhanced immune system, providing an opportunity for a broader anti-tumor effect without the selection pressure created by single antigen-targeting therapies.
Imvax’s platform delivers immunotherapy that is autologous – personalized to a patient’s entire unique tumor – and incorporates multiple mechanisms that stimulate both the innate and adaptive immune system. This broad spectrum effect could potentially also enhance the effects of other immunotherapies used in combination.
Imvax’s platform trains the immune system to comprehensively address a tumor’s entire antigenic signature. Because the immune system ignores ‘self’ antigens, Imvax’s platform inherently does not encourage off-tumor immune attack.
Imvax’s platform uses overnight tumor tissue processing to prepare its proprietary chambers for implantation. By contrast, many emerging therapies targeting one or a small number of antigens are based on expensive, difficult-to-manufacture cell therapy techniques.
Imvax’s platform begins with tumor samples from resection, commonly part of the standard of care for solid tumors. Rapid transition to the implantation step also facilitates integration into the standard of care.
Hear from our team about their motivations, experiences and aspirations at Imvax.
Imvax is committed to creating an inclusive community where every individual is treated with dignity and respect. Fostering a culture in which we celebrate and embrace every team member’s authentic self is vital to our mission. By welcoming varied perspectives and voices, we create a better environment and encourage the curiosity and creativity that are essential ingredients for medical innovation.
Imvax offers a comprehensive and highly competitive benefits package and is an equal opportunity employer that celebrates and embrace every team member’s authentic self as vital to our mission.
“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehend erit in volup.”
At Imvax, we know that making transformational therapies a reality takes many minds and different technologies working together. We welcome expressions of interest in collaborating to deliver a new generation of immunotherapies. We are a passionate, patient-focused, data-driven platform company.
Chief Executive Officer
Chief Executive Officer
As Chief Executive Officer, John P. Furey leads the company’s development of its novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers. He also serves on the Imvax Board.
Most recently, John was Chief Operating Officer of Spark Therapeutics, Inc., where he led the successful US launch of LUXTURNA™, the first FDA-approved gene therapy for a genetic disease, and contributed to the build out of Spark as a fully integrated company. Prior to Spark, Mr. Furey served as Senior Vice President and Head of Global Operations at Baxalta, where he transformed the company’s global operations into a first-in-class supply chain network for rare diseases and led the 14,000-employee manufacturing, quality, engineering and process development organization. Earlier in his career, Mr. Furey initiated the restructuring and ultimate divestiture of Baxter International’s vaccines franchise to Pfizer. While at Pfizer, he transformed the China vaccine business into one of the company’s fastest growing units.
Mr. Furey also currently serves as non-executive director at Adaptimmune, a leader in T-cell therapy, and is an indepdent board member of Sensorion, a pioneering clinical-stage biopharmaceutical company developing therapies for the ear.
Mr. Furey earned an Executive MBA (Pharmaceutical Marketing) from St. Joseph’s University, in Philadelphia, a Bachelor of Science with Honors from Trinity College, Dublin, and a Diploma in Environmental Health from the Dublin Institute of Technology.
Co-Founder, Chief Medical Officer
Co-Founder, Chief Medical Officer
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Co-Founder
Co-Founder
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Chief Scientific Officer
Chief Scientific Officer
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Chief Operating Officer
Chief Operating Officer
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Chief Regulatory Officer
Chief Regulatory Officer
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Chief Legal Officer
Chief Legal Officer
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Chief Financial Officer
Chief Financial Officer
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Co-Founder, Chairman of the Board
Co-Founder, Chairman of the Board
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Ziff Capital Partners
Ziff Capital Partners
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Co-Founder
Co-Founder
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
TLP Investment Partners LLC
TLP Investment Partners LLC
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
President, Brind Investments, Inc.
President, Brind Investments, Inc.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Board Advantage, LLC
Board Advantage, LLC
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Chief Executive Officer
Chief Executive Officer
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Wild Group Management AG
Wild Group Management AG
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Fiscus Ventures & Reimagined Ventures
Fiscus Ventures & Reimagined Ventures
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Epizyme
Epizyme
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
UT Health San Antonio
UT Health San Antonio
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
Euismod felis id nunc accumsan convallis. Nulla consectetur arcu nec libero congue, ut molestie dui consectetur. In eleifend dui finibus libero fermentum eget elementum sapien auctor. Cras nibh dui, pretium in ex vehicula, iaculis viverra elit. Phasellus mauris leo, ornare at erat vitae, lobortis malesuada enim. Etiam varius accumsan libero, id vulputate libero volutpat non.
What does a Phase 2 trial investigate?
Generally, Phase 2 trials utilize the same dose and schedule of a drug determined to be safe and effective in Phase 1, but in a larger group of patients. The goals of a Phase 2 trial are to further determine the safety of a new drug and to evaluate the effectiveness of a new drug or drugs.
What is the design of the Phase 2 study?
Based on the encouraging results in the Phase 1 trials, Imvax has initiated a Phase 2b trial with IGV-001 in 93 patients with ndGBM. The trial will be run at several cancer centers, generally in the Eastern half of the United States. All patients will have biodiffusion chambers placed in the abdomen after surgery for the brain tumor. One-third (1/3) of the patients will have a placebo (inactive drug) in the biodiffusion chambers, and two-thirds (2/3) will have active IGV-001 in the biodiffusion chambers. The study is blinded, meaning you, your doctors, and your treatment team will not know if you are receiving IGV-001 or the placebo. In rare cases, your treatment can be revealed (unblinded) if your doctors feel that information is important to know for additional medical care or an emergency.
All patients will receive standard chemotherapy (temozolomide) with radiation followed by chemotherapy (temozolomide) following recovery from brain tumor surgery, just as was done in the Phase 1 study.
What are the requirements to enroll in the Phase 2 study?
The primary requirement for eligibility in the Phase 2 study is that you must have glioblastoma that is newly diagnosed, without starting chemotherapy or radiation yet. Other important requirements for your eligibility in the study, such as your general health and other medications will be reviewed and discussed with you by your doctor and research team. Not all patients with ndGBM will be eligible for this study.
What happens if I’m interested in enrolling?
Once the study, including risks, benefits, and other treatment options, have been discussed with you and if you are willing to proceed in the study, you will be asked to sign an informed consent form, acknowledging that you are willing to proceed with the study treatment. You can withdraw your consent to participate in the study at any time and for any reason you decide. Procedures that you may be financially responsible for will also be discussed, although in most cases these procedures can be billed to your insurance company.
How is my eligibility determined?
Once you sign the consent form, your research team will begin scheduling and performing various tests required to determine your eligibility for the study. These will include items such as scans, blood tests, and tests on your heart, for example. When all of these tests are performed, and the results are satisfactory, you will be scheduled for surgery on your brain tumor. Your treatment team will provide a schedule for all of these. If you are determined to not be eligible for the study, your treatment team will discuss other treatment options with you.
Where is the study taking place?
You can find the study listing (NCT04485949) in www.clinicaltrials.gov.These are currently the sites participating in the study:
Additional study sites will be added soon. Please check back regularly for additional information or
get in touch with our clinical affairs team with any other key questions.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Sed viverra tellus in hac habitasse platea dictumst. Tincidunt nunc pulvinar sapien et ligula ullamcorper malesuada proin libero. Pretium quam vulputate dignissim suspendisse in est ante in. Amet facilisis magna etiam tempor orci eu. Id volutpat lacus laoreet non curabitur gravida arcu ac tortor. Faucibus et molestie ac feugiat sed lectus vestibulum mattis. Duis ut diam quam nulla porttitor massa id. Eget sit amet tellus cras adipiscing enim eu turpis egestas. Mauris cursus mattis molestie a iaculis at erat pellentesque.
Feugiat nisl pretium fusce id velit ut tortor pretium viverra. Vitae justo eget magna fermentum iaculis eu. Lectus sit amet est placerat in egestas erat. Proin gravida hendrerit lectus a. Egestas egestas fringilla phasellus faucibus scelerisque eleifend donec. Amet venenatis urna cursus eget nunc scelerisque viverra. Massa placerat duis ultricies lacus. Ullamcorper dignissim cras tincidunt lobortis feugiat vivamus at. Malesuada fames ac turpis egestas maecenas. Enim neque volutpat ac tincidunt vitae. Pellentesque pulvinar pellentesque habitant morbi tristique senectus.
Accumsan lacus vel facilisis volutpat. Pulvinar neque laoreet suspendisse interdum consectetur libero id. Accumsan sit amet nulla facilisi. Ipsum dolor sit amet consectetur adipiscing elit. Aliquet porttitor lacus luctus accumsan tortor posuere. Sagittis vitae et leo duis. Vitae congue eu consequat ac. Ullamcorper dignissim cras tincidunt lobortis feugiat vivamus. Dignissim sodales ut eu sem integer vitae justo. Leo urna molestie at elementum eu.
Et tortor consequat id porta. A diam maecenas sed enim ut sem viverra aliquet eget. Ullamcorper velit sed ullamcorper morbi. Nullam ac tortor vitae purus faucibus ornare. Etiam dignissim diam quis enim lobortis. Eleifend donec pretium vulputate sapien nec sagittis aliquam malesuada. Cursus mattis molestie a iaculis at. Mauris ultrices eros in cursus turpis. Dictum fusce ut placerat orci nulla pellentesque dignissim enim. Commodo odio aenean sed adipiscing diam donec adipiscing tristique risus.
Non sodales neque sodales ut etiam sit amet nisl. Amet justo donec enim diam. Eget magna fermentum iaculis eu non diam phasellus vestibulum lorem. Metus dictum at tempor commodo. In fermentum et sollicitudin ac orci phasellus egestas tellus. Metus dictum at tempor commodo ullamcorper a lacus vestibulum sed. In pellentesque massa placerat duis ultricies lacus sed turpis. Adipiscing elit pellentesque habitant morbi tristique senectus et. Pellentesque habitant morbi tristique senectus. Accumsan tortor posuere ac ut consequat semper viverra. Adipiscing commodo elit at imperdiet dui accumsan sit amet.
Clinical trials are highly regulated by federal regulatory agencies. You can find additional information at the website of The U.S. Food and Drug Administration.
Additional information can be found in the following websites:
• American Cancer Society (ACS)
• National Cancer Institute (NCI)
• National Comprehensive Cancer Network (NCCN)
• ClinicalTrials.gov
Patient Advocacy Groups (PAGs) are organizations that provide vital support for the GBM community. We have provided the links below for your convenience.
